HanAll Biopharma and Daewoong Pharmaceutical Invest in Turn Biotechnologies
Turn has developed a novel cell rejuvenating platform with significant potential for application in an array of age-related diseases
Turn has developed a novel cell rejuvenating platform with significant potential for application in an array of age-related diseases
The peptide-based vaccine induces a t cell-dependent response
Collaboration awarded €3 million grant by the Bill & Melinda Gates Foundation
The groundbreaking, uniquely robust Robert A. Winn Diversity in Clinical Trials Award Program is on track to train more than 500 individuals from diverse backgrounds by 2027
Daewoong Pharmaceutical, HanAll Biopharma join Astellas Venture Management and other VCs in oversubscribed funding round to accelerate Turn Bio's preclinical advances in multiple therapeutic areas
Results from pre-clinical research show iron-like compound hold promise for treating patients with glioblastoma, an aggressive brain cancer
Dr. Matthew Weiss presents data on patient organoids & cancer care at the American Surgical Association annual meeting
Collaboration to target bacterial and viral pathogens including HIV, SARS-CoV-2, antimicrobial-resistant pathogens, and tuberculosis
If authorized by the USFDA, the Proof Lab Test System may be used to deliver accurate, actionable, lab-quality results for Covid-19 in as little as 18 minutes
The kidney swap transplant procedure provides a solution to a critical shortage of compatible kidneys for patients suffering from kidney failures in India
Subscribe To Our Newsletter & Stay Updated